Mostrar el registro sencillo del ítem

dc.contributor.authorSuñer-Carbó, Joaquim
dc.contributor.authorCalpena-Campmany, Ana
dc.contributor.authorHalbaut-Bellowa, Lyda
dc.contributor.authorClares Naveros, Beatriz 
dc.contributor.authorRodriguez-Lagunas, María José
dc.contributor.authorBarbolini, Elena
dc.contributor.authorZamarbide-Losada, Joanna
dc.contributor.authorBoix-Montañés, Antonio
dc.date.accessioned2019-03-04T13:32:16Z
dc.date.available2019-03-04T13:32:16Z
dc.date.issued2019-02-02
dc.identifier.citationSuñer-Carbó, Joaquim; Calpena-Campmany, Ana; Halbaut-Bellowa, Lyda; Clares Naveros, Beatriz; Rodriguez-Lagunas, María José; Barbolini, Elena; Zamarbide-Losada, Joanna; Boix-Montañés, Antonio. Biopharmaceutical Development of a Bifonazole Multiple Emulsion for Enhanced Epidermal Delivery. Pharmaceutics 2019, 11, 66. [ doi:10.3390/pharmaceutics11020066]es_ES
dc.identifier.issn1424-8247
dc.identifier.urihttp://hdl.handle.net/10481/54886
dc.description.abstractEfficient topical delivery of imidazolic antifungals faces the challenge of overcoming its limited water solubility and its required long-lasting duration of treatments. In this paper, a hydrophilic multiple emulsion (ME) of Bifonazole (BFZ) is shown to maximize its skin retention, minimize its skin permeation, and maintain an acceptable level of being harmless in vivo. The formulations were pharmaceutically characterized and application properties were assessed based on viscosity measurements. Non-Newtonian pseudoplastic shear thinning with apparent thixotropy was observed, facilitating the formulation retention over the skin. The in vitro release profile with vertical diffusion cells showed a predominant square-root release kinetic suggesting an infinite dose depletion from the formulation. Ex vivo human skin permeation and penetration was additionally evaluated. Respective skin permeation was lower than values obtained with a commercial O/W formulation. The combination of amphoteric and non-ionic surfactants increased the bifonazole epidermal accumulation by a factor of twenty. This fact makes the possibility of increasing its current 24 h administration frequency more likely. Eventual alterations of skin integrity caused by the formulations were examined with epidermal histological analysis and in vivo preclinical measurements of skin elasticity and water retrograde permeation. Histological analysis demonstrated that the multiple emulsions were harmless. Additionally, modifications of in vivo skin integrity descriptors were considered as negligible.es_ES
dc.description.sponsorshipThere are no specific funding sources or universitary fellowship for this experimental work. Article processing charges were partially supported by University of Barcelona.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectMultiple emulsiones_ES
dc.subjectBifonazolees_ES
dc.subjectPseudoplastices_ES
dc.subjectDrug releasees_ES
dc.subjectSkin penetrationes_ES
dc.subjectSkin permeationes_ES
dc.subjectSkin integrityes_ES
dc.subjectTEWLes_ES
dc.subjectEpidermal histologyes_ES
dc.titleBiopharmaceutical Development of a Bifonazole Multiple Emulsion for Enhanced Epidermal Deliveryes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/pharmaceutics11020066


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España